ArticlePloS one2026
Hyperbaric oxygen treatment and toll-like receptor 5 in radioprotection of epithelial cells.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIrradiation of tumours in the pelvic area may lead to adverse effects such as vaginal fibrosis and dyspareunia. We investigated the radioprotective effects of hyperbaric oxygen (HBOT) and toll-like receptor 5 (TLR5) in epithelial cells. METHODS AND MATERIALS: Endothelial cells (HUVEC), urothelial cells (UROtsa), and cervical epithelial cells (HeLa) were irradiated with 6 Gy and subsequently underwent HBOT. Cells were counted and qPCR was performed on HeLa for the expressions of TLR5, downstream signalling molecules, oxidative stress, and cytokines. The effects of the TLR5 agonist flagellin and the TLR5 antagonist TH1020 on radiation-induced cell death and oxidative stress were assessed.
resultsHBOT attenuated radiation-induced epithelial cell death. In HeLa, radiation reduced TLR5, TRIF, NRF2, HIF-α and catalase expression. HBOT reversed their expression. The TLR5 agonist flagellin protected against radiation-induced cell death in HeLa and the TLR5 antagonist TH1020 inhibited the radioprotective effects by flagellin.
conclusionsHBOT antagonizes radiation-induced cell death and normalizes the expressions of antioxidants, TLR5 and connected downstream signalling transcripts. TLR5 signalling contributes to protection from radiation-induced epithelial cell death, which supports further exploration of combined HBOT-TLR5-targeted strategies for mucosal radioprotection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.